H.C. Wainwright raised the price target for the Iterum Therapeutics plc (NASDAQ:ITRM) stock from “a Neutral” to “a Buy”. The rating was released on March 15, 2021. We previously noted in another research note published on June 02, 2020 by RBC Capital Mkts that downgraded the stock from an Outperform to a Sector perform with a price target of $2 for ITRM stock. In their research brief published June 21, 2019, H.C. Wainwright analysts initiated the Iterum Therapeutics plc stock to Buy with a price target of $17.
Historical Earnings Surprises and Revenue Forecasts
Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of -$0.27 during the last quarter as opposed to a consensus estimate of -$0.19, which indicates the company missed its estimate by -$0.08, which implies that the company surprised the market by -42.10%. It appears that the average earnings per share estimate for the current quarter (ending in Mar 2021) is -$0.07. This is an average of 2 analysts’ earnings, where the high earnings per share estimate is -$0.06 and the low earnings per share estimate is -$0.08.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Iterum Therapeutics plc (NASDAQ:ITRM) dipped -4.76% to close Tuesday’s market session at $1.20, lower as compared to yesterday’s close. The stock price fluctuated between $1.18 and $1.27 throughout the trading session with the volume trading being 5518809 shares, which represented a significant variation when compared to the three months average volume of 25.44 million shares. The firm’s stock price fluctuated 12.15% within the last five trades and -14.89% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 128.44% in the last 6 months and -24.05% was subtracted to its value over the previous 3 months. ITRM stock is trading at a margin of -6.94%, -21.71% and 10.00% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, ITRM deals in the Healthcare domain. The stock is trading -80.07 percent below its 52-week high and 166.08 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -62.52. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Iterum Therapeutics plc’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $202.90 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.30 percent of Iterum Therapeutics plc shares are owned by insiders, and 9.10 percent are held by financial institutions. DENNER ALEXANDER J, the 10% Owner at Iterum Therapeutics plc (ITRM) has sold 10,619,949 shares of firm on Feb 12 at a price of $2.27 against the total amount of $24.11 million. In another inside trade, DENNER ALEXANDER J, 10% Owner of Iterum Therapeutics plc (NASDAQ:ITRM) sold 10,000,000 shares of the firm on Feb 11 for a total worth of $25.9 million at a price of $2.59. An inside trade which took place on Jan 26, President & CEO of Iterum Therapeutics plc Fishman Corey N. sold 85,445 shares of firm against total price of $0.15 million at the cost of $1.73 per share.